The primary objective of this study is to evaluate the safety and effectiveness of performing 0.50 D cylinder correction on the RxSight Light Adjustable Lens (LAL) in patients who have undergone implantation with the FDA approved, commercially available LAL.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
Study eye will undergo Light delivery Device treatments
Cleveland Eye Clinic
Brecksville, Ohio, United States
Vance Thompson Vision Clinic
Sioux Falls, South Dakota, United States
Mean Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups
Time frame: Post Op Month 3
Change in Manifest Refraction Cylinder (MRCYL) Compared Between the Three Study Groups, LAL Treatment Group and Historical Control Groups
Time frame: Post Op Month 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.